Clinical Study

Clinical Efficacy of Intravitreal Ranibizumab in Early and Mid-Idiopathic Choroidal Neovascularization

Figure 2

Fluorescein angiography and horizontal optic coherence tomography findings in a patient in the interim group. (a) Fluorescein angiography at late stage and (b) horizontal optic coherence tomography cross-sections of the macula from in the left eye of a 20-year-old woman with subretinal idiopathic choroidal neovascularization, subretinal fluid, and intraretinal edema. Her BCVA was 44 letters at baseline. Three months later, the BCVA was 54 letters, and subretinal fluid had reduced (c). The retinal pigment epithelium had also become smaller (d). Six months after the injection, compared to the conditions at 3 months after injection, fluorescein leakage appeared again (e), subretinal fluid increased (f), and BCVA was 49 letters. Therefore, the 2nd injection was administered. At 12 months, the BCVA was 57 letters, subretinal fluid had disappeared (g), and the retinal profile was normal except for minimally elevated retinal pigment epithelium (h).
382702.fig.002a
(a)
382702.fig.002b
(b)
382702.fig.002c
(c)
382702.fig.002d
(d)
382702.fig.002e
(e)
382702.fig.002f
(f)
382702.fig.002g
(g)
382702.fig.002h
(h)